Gastroparesis - Pipeline Review, H2 2015

Date: September 9, 2015
Pages: 40
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GF229CDE3C4EN
Leaflet:

Download PDF Leaflet

Gastroparesis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Gastroparesis - Pipeline Review, H2 2015’, provides an overview of the Gastroparesis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Gastroparesis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroparesis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroparesis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroparesis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Gastroparesis Overview
Therapeutics Development
Pipeline Products for Gastroparesis - Overview
Pipeline Products for Gastroparesis - Comparative Analysis
Gastroparesis - Therapeutics under Development by Companies
Gastroparesis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gastroparesis - Products under Development by Companies
Gastroparesis - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
RaQualia Pharma Inc.
Gastroparesis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
camicinal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NG-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00201894 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
velusetrag hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gastroparesis - Recent Pipeline Updates
Gastroparesis - Dormant Projects
Gastroparesis - Product Development Milestones
Featured News & Press Releases
May 18, 2015: Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of Gastroparesis in 'Poster of Distinction' at Digestive Disease Week (DDW) 2015
Mar 12, 2015: Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the Treatment of Gastroparesis
Jan 07, 2014: RaQualia Receives a Patent Allowance for Motilin Receptor Agonist in the USA
Jan 08, 2013: Theravance And Alfa Wassermann Announce Initiation Of Phase II Study With Velusetrag For Gastroparesis
Sep 14, 2012: RaQualia Pharma's Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Gastroparesis, H2 2015
Number of Products under Development for Gastroparesis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2015
Gastroparesis - Pipeline by RaQualia Pharma Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gastroparesis Therapeutics - Recent Pipeline Updates, H2 2015
Gastroparesis - Dormant Projects, H2 2015

LIST OF FIGURES

Number of Products under Development for Gastroparesis, H2 2015
Number of Products under Development for Gastroparesis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

GlaxoSmithKline Plc
RaQualia Pharma Inc.
Skip to top


Ask Your Question

Gastroparesis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: